The maker of Ozempic and federal regulators are sending out warnings about counterfeit versions of the anti-diabetic drug ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

New data from Novo Nordisk’s phase 3 trial of an oral ... but Eli Lilly is in hot pursuit. The 50 mg oral semaglutide pill achieved a 15.1% weight loss in the phase 3 OASIS study involving ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products ... 10% weight loss at a daily dose of 50mg at 12 weeks, with patients taking 100mg per day ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk NVO shares have lost 15.2% so far ... NVO’s success in the past few years is underscored by its marketed semaglutide (GLP-1 agonist) medicines. The company has a strong presence ...

Less than five years on from when Novo Nordisk's semaglutide drug received FDA approval for weight loss (Wegovy), the Danish pharmaceutical company has announced it will seek regulatory approval ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly ...

Novo Nordisk is actively exploring additional uses for semaglutide, including evaluating Wegovy for heart failure in diabetes and obesity patients and Ozempic as a treatment for T2D and chronic ...

Based on SOUL findings, Novo Nordisk submitted a label extension ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound ...